Overview

Modulation of the Brain Excitatory/Inhibitory (E/I) Balance in Autism Spectrum Disorder (ASD)

Status:
Unknown status
Trial end date:
2020-02-02
Target enrollment:
Participant gender:
Summary
This study investigates the brain response to a single acute dose of Arbaclofen, the R-enantiomer of the GABA-B agonist Baclofen, compared to a single dose of placebo in healthy men with and without autism spectrum disorder.
Phase:
N/A
Details
Lead Sponsor:
King's College London
Treatments:
Baclofen